Life Science Leader Feature Articles

  1. Behind The Scenes Of Allergan’s Social Contract
    9/8/2017

    The story behind Allergan’s bold decision to formalize its social contract with patients told to our Chief Editor by Brent Saunders, Allergan’s chairman, president, and CEO.

  2. P3s: How To Get The Good …Without The Bad
    9/8/2017

    At this year’s BIO International Convention in San Diego (June 19 – 22), I moderated a session, Navigating A Clear Path To Public-Private Partnerships, and we talked about the good, the bad, and the ugly of P3s. After a brief introduction, the first question was posed, resulting in the following edited dialogue.

  3. Cytokinetics: Keeping Its Sights On Independence
    9/8/2017

    Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.

  4. Reaching A Turning Point With An Unusual Cancer Therapeutic
    9/8/2017

    Sometimes it pays to go against the grain. In 2013 Life Science Leader published an article describing the efforts of Dr. Ray Takigiku to establish Bexion Pharmaceuticals, a startup biotechnology firm, located in Covington, KY.

  5. Sanat Chattopadhyay — Shaping Merck’s Manufacturing Future
    8/9/2017

    It’s been a little over a year since Sanat Chattopadhyay was named president of Merck Manufacturing Division (MMD), and this month he gives an exclusive interview on the status of the division’s transformational turnaround.

  6. Chasing Invention: Jeffrey Kindler At The Helm Of Centrexion
    8/9/2017

    As former chairman and CEO of Pfizer, Jeffrey Kindler dealt with the frustrating conundrum of ballooning R&D budgets tracking alongside plunging R&D productivity. Now as he leads this chronic pain biopharma startup, he has a whole new set of challenges.

  7. Rising Out Of Takeda’s Reorganization: New Materials & Innovation
    8/9/2017

    “You don’t have time to invest in basic research and wait 10 years. You have to go find individuals and companies doing exciting research, engage them, and progress those new technologies through collaborations and funding,” explains Takeda’s Vincent Ling.

  8. Ipsen In The USA — Building & Leading The Subsidiary As Startup
    8/9/2017

    Cynthia Schwalm, president, North American commercial operations for Ipsen, gives the backstory of what happened when this company decided to change its approach to the U.S. market.

  9. CEOs 40 & Under: The Future of Pharma Innovation
    7/7/2017

    To take the pulse of the biopharma industry, Life Science Leader tracked down four CEOs age 40 and under. These are the people at the forefront of innovation — something that is no easy task in a heavily regulated, patient-centered industry. Biotech is not tech. Heading up a company that is developing a pharmaceutical is a lot more challenging and riskier than starting one in your garage that is developing the next mobile phone app.

  10. Astellas Puts Oncology Front & Center
    7/7/2017

    Astellas has placed a big emphasis on oncology this year, pointing to its many assets, particularly in targeted therapies that are later stage, but also focusing through partnerships on immuno-oncology (IO). A conversation with Drs. Steven Benner, head of oncology, and Peter Sandor, head of oncology marketing strategy, follows.